NEWS
Making it easy for our investors to stay current with our portfolio companies and their industries.
May 29, 2025
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
May 28, 2025
Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon
May 13, 2025
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
GE HealthCare and Raydiant Oximetry accelerate innovation in fetal oxygen saturation technology
May 6, 2025
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France